Search results
NGS: the road to personalising cancer care
Medical Device Network via Yahoo Finance· 1 day ago“But with comprehensive testing, the RNA sequencing part of the test identified a Neurotrophic tyrosine receptor kinase (NTRK) gene fusion,” Baehner...an...
Ethylene oxide emissions from 2 plants could have raised cancer risks for Illinois residents, report...
Chicago Tribune via Yahoo News· 2 hours agoPeople living near two Lake County industries could face significantly greater risks of developing...
OpenAI Expands Healthcare Push With Color Health’s Cancer Copilot
The Wall Street Journal· 5 days agoCIO JOURNAL OpenAI is working with startup Color Health to expand the use of artificial intelligence...
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks via Yahoo Finance· 11 hours agoCSTL offers its products to skin cancer, gastroenterology, and mental health markets. Castle...
Cancer Kills Millions of Dogs. Will Immunotherapy Prolong Their Lives?
New York Times· 14 hours agoDr. Hans Klingemann, pioneering immunotherapy scientist, has studied whether the innovative...
Insider Selling: CEO and President Steven Chapman Sells Shares o
Guru Focus· 5 days agoOn June 17, 2024, Steven Chapman, CEO and President of Natera Inc (NTRA, Financial), executed a sale of 6,105 shares of the company. The transaction was filed on June 18, ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 1 day agoThe company says it will have the results of that study soon. Meanwhile, Pfizer began testing its...
The Watchlist: 3 Stock Spinoffs Coming Soon (Be Ready to Buy)
InvestorPlace· 5 days agoStock spinoffs to buy can be tricky finds. Many times the parentcompany will offload debt and other...
In Brief This Week: Devyer, Thermo Fisher, Olink, Prenetics, Genetic Technologies, More
GenomeWeb News· 10 hours agoThe agreement now grants Thermo Fisher exclusive rights to globally commercialize Devyser’s post-transplant next-generation sequencing test portfolio, which includes the One ...
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Dive via Yahoo Finance· 12 hours agoA medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two...
